Content navigation:Another domestic new crown vaccine has been approved for conditional listing! How effective is Kexing's new crown disease protection? China's first new crown vaccine is on the market. What are the advantages and disadvantages of various vaccines? Is the domestically-made new crown inactivated vaccine expected to be on the market at the end of December? Which related listed companies are beneficial to the new crown vaccine? The new coronary pneumonia inactivated vaccine is expected to be on the market at the end of December. How safe is the vaccine? 110 new crown pneumonia vaccines are racing, why is China the real "leader"?
Q1: Another domestically-made new crown vaccine has been approved and listed on conditional conditions! How effective is Kexing's new crown disease protection?
On February 6, 2021, Kexing Holding Biotechnology Co., Ltd. announced that the State Drug Administration had approved the company’s subsidiary Beijing Kexing Zhongwei Biotechnology on February 5 according to law. The new coronavirus inactivated vaccine Kellyvo developed by Technology Co., Ltd. ("Kexing Zhongwei") is conditionally marketed in China. In June 2020, Kerlaifu was the first to be approved for emergency use in China. Beginning in January 2021, countries such as Indonesia, Turkey, Brazil and other countries have successively approved the emergency use of Kerlaifu in the local area. At present, these countries mainly vaccinate medical staff, the elderly, and high-risk groups. Relevant countries have recognized the effects of the Kellyford inactivated vaccine and believe that the Kellyford inactivated vaccine has a significant effect on reducing medical treatment, hospitalization, severe illness and death caused by new coronary pneumonia, and is of great significance for epidemic prevention and control.
The protective efficacy of Kerlaifu inactivated vaccine
1. Clinical trials for adults over 18 years old and minors aged 3-17 years old. The new crown inactivated vaccine developed by Kexing Zhongwei has undergone rigorous animal experiments and phase I and II clinical studies in the early stage. At present, the domestically completed phase I/II clinical studies for adults and elderly people over 18 years old , Clinical trials for minors aged 3-17 years have completed the enrollment of all subjects. The number of domestic subjects exceeds 2,200. The results show that the vaccine has good safety and immunogenicity for people of all ages.
2. From July 21, 2020, Kexing Zhongwei will successively choose Brazil and Chile in South America, Indonesia in Southeast Asia and Turkey in the Middle East, which are located in different regions and have their own characteristics. Featured countries carry out phase III clinical research. These studies used the same batch of vaccines, followed the same immunization procedures (0,14 procedures), and were independently carried out in accordance with the requirements of the drug clinical trial quality management regulations (GCP), with a total number of 25,000 people enrolled.
Phase III clinical studies were carried out in Brazil and Turkey to evaluate the effects of Kellyford in high-risk groups and the general population. Both countries adopt a multi-center, randomized, double-blind, placebo parallel-controlled design. The primary endpoint is the incidence of new coronavirus-caused disease (COVID-19) 14 days after vaccination with 2 doses of vaccine or placebo.
(1) The effectiveness of Brazil for the protection of medical personnel aged 18 and above: As of December 16, 2020, a total of 12,396 studies on medical personnel aged 18 and above were included in Brazil Of the subjects, 253 valid cases during the monitoring period were obtained. The protective effect of preventing the disease caused by the new coronavirus (COVID-19) 14 days after vaccination according to the procedure of 0,14 days is: the protective effect for hospitalization, severe illness and death cases is 100.00%, for patients with obvious symptoms and need The protective effect of medical intervention for new coronary cases is 83.70%, and the protective effect for all new coronary cases, including mild cases that do not require medical intervention, is 50.65%.
(2) Protective efficacy for 18-59 year olds at high-risk medical staff and normal-risk general population: The target population of the Phase III clinical trial in Turkey is 18-59 Years oldHigh-risk medical staff (K-1) and the general population at normal risk (K-2), as of December 23, 2020, 918 subjects in the K-1 cohort were enrolled, and the K-2 cohort was enrolled There were 6,453 subjects, and a total of 7371 cases were enrolled. Among them, 1322 subjects completed two doses of vaccination and entered the 14-day observation period after the second dose of vaccination. Based on the analysis of 29 cases, the protective efficacy against COVID-19 after 14 days of vaccination with two doses of the vaccine on the 0,14 day program was 91.25%.
Q2: China’s first new crown vaccine is launched What are the advantages and disadvantages of various vaccines?
On the last day of 2020, December 31, according to the news released by the Joint Prevention and Control Mechanism of the State Council, Sinopharm Sinopharm's new crown vaccine was approved by the State Food and Drug Administration for conditional listing. This is the first new crown vaccine launched in my country. Zeng Yixin, deputy director of the National Health Commission, said: “The basic attributes of vaccines are still public products, and the price may vary according to the scale of use. But a major premise is that it must be provided for free for all people. This is a major premise. ”
Since the fight against the new crown epidemic, my country has been developing effective vaccines. We all know that the new crown virus acts on the elderly with weaker resistance, so the research and development of vaccines is first considered for the design of the audience. China's first new crown vaccine was launched, and it has attracted much attention both at home and abroad. Because China is currently the best country in the world to effectively prevent and control the epidemic, and now many foreign countries have a very serious epidemic, and the death toll is still increasing. So what are the advantages and disadvantages of the various vaccines developed in my country?
First, inactivated vaccines. High safety, mature technology, only stimulate humoral immunity, and production is restricted by site. It cannot simulate the infection process of the virus, and the stimulation of the immune system is relatively weak. Usually only antibody-based humoral immunity is produced; live pathogens need to be cultivated first, and then inactivated to make vaccines, which requires high levels of biological safety in the production workshop, and yields Also subject to certain restrictions.
Second, recombinant protein vaccines have high efficacy and safety, and high production capacity.
Third, viral vector vaccines and nucleic acid vaccines have the highest production capacity, but there are significantly more adverse reactions. The safety remains to be seen.
In fact, in my opinion, the safest and most secure is inactivated vaccines. Because of this type of vaccine, our scientists have experience in research and development. The current inactivated vaccines include inactivated polio vaccine, inactivated hepatitis A vaccine, and hand-foot-mouth vaccine. Commonly used vaccines for the entire population include rabies vaccines. At the same time, these vaccines have a very good policy, that is, the country’s free policy, without having to pay for it.
Q3: The domestically-made new crown inactivated vaccine is expected to be on the market at the end of December?
Some news has said that, but when it will be launched, we will have to wait for official news.
Q4: Which relevant new crown vaccines will be launched? Is the business profitable?
The domestically-made new crown vaccine is finally coming. Winter is here, and the epidemic situation abroad has become more serious. There are also a few cases in China. With the vaccine, it is a good thing for the public. Related concept stocks have risen last week. In one wave, I saw an analysis of the pharmaceutical stock sector on the WeChat News on the weekend, and also made an analysis of related listed companies. The content was written in great detail. If you are interested, you can read related analysis articles.
Q5:The new coronary pneumonia inactivated vaccine is expected to be on the market at the end of December. How safe is the vaccine?
The new coronary pneumonia inactivated vaccine is expected to be on the market at the end of December. How safe is the vaccine?
It is reported that the domestically-made new crown inactivated vaccine is expected to be on the market at the end of December 2020.
What is the safety and protection rate of the vaccine? Let us find out.
Liu Jingzhen, Secretary of the Party Committee and Chairman of China National Pharmaceutical Group Co., Ltd. Said that after the third phase of the international clinical trial is over, the inactivated vaccine can enter the approval process. It is expected to be on the market at the end of December this year, and the production of this batch of vaccines in Beijing can reach 120 million.meter. The annual output in Wuhan can even reach 100 million doses.
According to the safety of the vaccine, because in the evaluation of multiple clinical trials, the The immunity, epidemic prevention and safety of the vaccine have been achieved. The standard verifies the safety and immunogenicity of the vaccine. By comparing the Phase II clinical trial with the Phase I clinical trial, the safety of the vaccine in a wider range of people and the immunogenicity of the vaccine have provided further demonstration, and the information can be queried globally. This means that my country's medical standards and intellectual property system have enough confidence.
Regarding the protection rate of the vaccine, Liu Jingzhen, Secretary of the Party Committee and Chairman of China National Pharmaceutical Group Co., Ltd., said that the protection rate of one shot of the vaccine is about 97% because of the production of antibodies. It is slow, and grows slowly like a curve. Therefore, it usually takes about half a month to reach the level of resistance to the starlight virus. If a two-shot vaccine is given, the protection rate can even reach 100%.
And for now, this vaccine has already obtained a national patent, and
the approved vaccine has been approved for safety. , and the effectiveness is qualified, and will be mass-produced soon. It can be said that this vaccine has no side effects and is safe. We should maintain hope for our country’s key technologies and the development of future technologies. Our country’s scientific research technology and level are gradually improving, and we should continue to maintain an optimistic attitude!
Q6:110 new coronary pneumonia vaccines are racing, why is China the real "leader"?
Because China is the country that attaches the most importance to this epidemic among 110 countries, it can be seen from various measures and systems that China has shown a very high level of responsibility in responding to the epidemic, and China’s technology is leading the world. Yes, the new crown vaccine will definitely be developed first.